Years of scouring the bush and breeding work at The University of Queensland have resulted in new varieties of a native Australian plant valuable to the global pharmaceutical industry. Researchers ...

Truist Financial analyst Joon Lee maintained a Buy rating on Catalyst Pharma (CPRX – Research Report) today. The company’s shares closed yesterday at $22.21. Discover outperforming stocks and ...

Established in 1875, Bombay Gymkhana has been a cornerstone of Mumbai’s sporting and cultural landscape. Over the past century and a half, it has not only fostered cricket, rugby and other ...

Today, we will plunge into the realm of sportswear logos. The top 10 brands will be ranked according to how much they have affected this business. What comes to mind when you think about sportswear?

SAN RAFAEL, Calif., Jan. 13, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the company has initiated a legal action against Ascendis Pharma A/S for ...

Royalty Pharma (RPRX) announced two major steps to enhance shareholder value. First, the Board of Directors has agreed to acquire its external manager, RP Management. This transaction to simplify ...

Amy also shares the importance of getting to know the individuals behind the big Pharma logos, which helps patients to believe that these organisations “have a heart”. To listen to this ...

India has been traditionally quite strong in the pharma sector, with a low cost of manufacturing (30%–35% lower than in the US and Europe), cost-efficient R&D (about 87% less than in developed markets ...

(Image Credits: Pixabay) Amid the growing burden of non-communicable diseases and ageing population, the pharmaceutical sector has thrived tremendously over the recent years. Industry leaders ...

Overall, biopharma layoffs rose ever so slightly in 2024 compared to the year before, though the number of layoff rounds across Big Pharma skyrocketed by 281%. In 2024, Fierce Biotech reported 192 ...

Novo Nordisk, for its part, is expected to jump from 10th place to sixth this year, according to Evaluate Pharma’s consensus forecasts. Nevertheless, it’s Roche that’s been tipped to stand ...